23rd Jan 2017 10:37
LONDON (Alliance News) - Rex Bionics PLC on Monday said that it has been cleared to start a clinical trial of its REX robotic mobility device for patients with multiple sclerosis.
The UK National Health Service's National Institute for Health Research has approved the start of a clinical trial to evaluate the use of the device.
The trial will be conducted in Canterbury, and will assess the feasibility and safety of using the device for patients with multiple sclerosis who have moderate to severe mobility restriction. The primary end-point of this trial will be the completion of a transfer, stand, balance and walk rehabilitation programme over six weeks.
The first patient is expected to be recruited shortly, with preliminary data presented later in 2017.
"Our RAPPER II trial established the safety and feasibility of the REX in a single treatment. We are delighted that the specialists in Canterbury are now interested in exploring the use of REX in MS, and in a course of treatment over several weeks," said Chief Executive Crispin Simon in a statement.
Shares in Rex Bionics were untraded Monday morning, last closing at 20.50 pence.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2017 Alliance News Limited. All Rights Reserved.
Related Shares:
RXB.L